

# Daisuke Yabe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4949822/publications.pdf>

Version: 2024-02-01

176  
papers

7,759  
citations

87888

38  
h-index

53230

85  
g-index

185  
all docs

185  
docs citations

185  
times ranked

8792  
citing authors

#	ARTICLE	IF	CITATIONS
1	Crucial Step in Cholesterol Homeostasis. <i>Cell</i> , 2002, 110, 489-500.	28.9	861
2	Genetic Restriction of AIDS Pathogenesis by an SDF-1 Chemokine Gene Variant. <i>Science</i> , 1998, 279, 389-393.	12.6	674
3	GIP and GLP-1, the two incretin hormones: Similarities and differences. <i>Journal of Diabetes Investigation</i> , 2010, 1, 8-23.	2.4	467
4	Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12753-12758.	7.1	449
5	Regulated Step in Cholesterol Feedback Localized to Budding of SCAP from ER Membranes. <i>Cell</i> , 2000, 102, 315-323.	28.9	307
6	Liver-specific mRNA for Insig-2 down-regulated by insulin: Implications for fatty acid synthesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 3155-3160.	7.1	260
7	Insig-dependent Ubiquitination and Degradation of Mammalian 3-Hydroxy-3-methylglutaryl-CoA Reductase Stimulated by Sterols and Geranylgeraniol. <i>Journal of Biological Chemistry</i> , 2003, 278, 52479-52490.	3.4	254
8	Î² Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians. <i>Current Diabetes Reports</i> , 2015, 15, 602.	4.2	231
9	Japanese Clinical Practice Guideline for Diabetes 2016. <i>Diabetology International</i> , 2018, 9, 1-45.	1.4	215
10	Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. <i>Journal of Diabetes Investigation</i> , 2013, 4, 108-130.	2.4	207
11	DANCE, a Novel Secreted RGD Protein Expressed in Developing, Atherosclerotic, and Balloon-injured Arteries. <i>Journal of Biological Chemistry</i> , 1999, 274, 22476-22483.	3.4	170
12	Japanese Clinical Practice Guideline for Diabetes 2016. <i>Journal of Diabetes Investigation</i> , 2018, 9, 657-697.	2.4	158
13	Inhibition of Notch/RBP-J signaling induces hair cell formation in neonate mouse cochleas. <i>Journal of Molecular Medicine</i> , 2006, 84, 37-45.	3.9	157
14	Two incretin hormones GLP-1 and GIP: Comparison of their actions in insulin secretion and Î² cell preservation. <i>Progress in Biophysics and Molecular Biology</i> , 2011, 107, 248-256.	2.9	150
15	Fibulin-4 conducts proper elastogenesis via interaction with cross-linking enzyme lysyl oxidase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 19029-19034.	7.1	146
16	Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives. <i>Journal of Diabetes Investigation</i> , 2016, 7, 102-109.	2.4	144
17	Sterols block binding of COPII proteins to SCAP, thereby controlling SCAP sorting in ER. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11694-11699.	7.1	132
18	Notch/Rbp-j signaling prevents premature endocrine and ductal cell differentiation in the pancreas. <i>Cell Metabolism</i> , 2006, 3, 59-65.	16.2	103

#	ARTICLE	IF	CITATIONS
19	Calumenin, a Ca <sup>2+</sup> -binding Protein Retained in the Endoplasmic Reticulum with a Novel Carboxyl-terminal Sequence, HDEF. <i>Journal of Biological Chemistry</i> , 1997, 272, 18232-18239.	3.4	96
20	Multiple roles of Notch signaling in cochlear development. <i>Developmental Biology</i> , 2007, 307, 165-178.	2.0	94
21	Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 392-406.	11.4	91
22	Three mutations in sterol-sensing domain of SCAP block interaction with insig and render SREBP cleavage insensitive to sterols. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 16672-16677.	7.1	83
23	Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2014, 105, 302-312.	2.8	82
24	Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 378-388.	4.4	82
25	Little enhancement of meal-induced glucagon-like peptide-1 secretion in Japanese type 2 diabetes patients and healthy controls. <i>Journal of Diabetes Investigation</i> , 2010, 1, 56-59.	2.4	80
26	Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 795-800.	2.4	73
27	Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 1616-1620.	7.1	72
28	Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial. <i>Diabetologia</i> , 2016, 59, 453-461.	6.3	69
29	Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes. <i>Endocrine Journal</i> , 2010, 57, 119-126.	1.6	68
30	Evidence-based practice guideline for the treatment for diabetes in Japan 2013. <i>Diabetology International</i> , 2015, 6, 151-187.	1.4	65
31	ChREBP-Mediated Regulation of Lipid Metabolism: Involvement of the Gut Microbiota, Liver, and Adipose Tissue. <i>Frontiers in Endocrinology</i> , 2020, 11, 587189.	3.5	64
32	Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2012, 3, 70-79.	2.4	59
33	Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: a randomized, open-label, 3-arm parallel comparative, exploratory study. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 739-743.	4.4	57
34	Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 413-421.	2.3	53
35	Type 2 diabetes via Î²-cell dysfunction in east Asian people. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 2-3.	11.4	52
36	Mx2-interacting nuclear target protein (Mint) deficiency reveals negative regulation of early thymocyte differentiation by Notch/RBP-J signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 1610-1615.	7.1	50

#	ARTICLE	IF	CITATIONS
37	Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?. <i>Journal of Diabetes Investigation</i> , 2014, 5, 475-477.	2.4	45
38	Incretin actions beyond the pancreas: lessons from knockout mice. <i>Current Opinion in Pharmacology</i> , 2013, 13, 946-953.	3.5	42
39	Molecular Cloning, Characterization, and Chromosomal Localization of FKBP23, a Novel FK506-Binding Protein with Ca <sup>2+</sup> -Binding Ability. <i>Genomics</i> , 1998, 54, 89-98.	2.9	39
40	Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study. <i>Journal of Diabetes Investigation</i> , 2018, 9, 332-340.	2.4	38
41	Generation of a conditional knockout allele for mammalian Spen protein Mint/SHARP. <i>Genesis</i> , 2007, 45, 300-306.	1.6	37
42	Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: A report of five cases. <i>Journal of Diabetes Investigation</i> , 2018, 9, 445-447.	2.4	37
43	Human Calumenin Gene (CALU): cDNA Isolation and Chromosomal Mapping to 7q32. <i>Genomics</i> , 1998, 49, 331-333.	2.9	32
44	Rbpj regulates expansion of pancreatic epithelial cells and their differentiation into exocrine cells during mouse development. <i>Developmental Dynamics</i> , 2007, 236, 2779-2791.	1.8	32
45	Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. <i>Journal of Diabetes Investigation</i> , 2012, 3, 464-467.	2.4	31
46	Beta-cell replacement strategies for diabetes. <i>Journal of Diabetes Investigation</i> , 2018, 9, 457-463.	2.4	30
47	Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase III clinical trials. <i>Journal of Diabetes Investigation</i> , 2019, 10, 418-428.	2.4	27
48	GPR40 activation initiates store-operated Ca <sup>2+</sup> entry and potentiates insulin secretion via the IP3R1/STIM1/Orai1 pathway in pancreatic $\beta$ -cells. <i>Scientific Reports</i> , 2019, 9, 15562.	3.3	27
49	Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced $\beta$ -cell function. <i>Journal of Diabetes Investigation</i> , 2013, 4, 585-594.	2.4	25
50	Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin. <i>Diabetes Therapy</i> , 2012, 3, 14.	2.5	24
51	Sodium-glucose cotransporter-2 inhibitor and sarcopenia in a lean elderly adult with type-2 diabetes: A case report. <i>Journal of Diabetes Investigation</i> , 2020, 11, 745-747.	2.4	24
52	Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 442-447.	4.4	23
53	Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00183.	2.4	23
54	Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of DPP-4 inhibitors with other oral antidiabetic drugs. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 430-434.	4.4	22

#	ARTICLE	IF	CITATIONS
55	Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea. <i>Journal of Diabetes Investigation</i> , 2014, 5, 445-448.	2.4	21
56	Incretin concept revised: The origin of the insulinotropic function of glucagon-like peptide-1 – the gut, the islets or both?. <i>Journal of Diabetes Investigation</i> , 2018, 9, 21-24.	2.4	20
57	Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining $\beta$ -cell function and the achievement of the glycated hemoglobin target 1 year after initiation. <i>Journal of Diabetes Investigation</i> , 2018, 9, 822-830.	2.4	20
58	Dipeptidyl-peptidase-4 inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations. <i>Journal of Diabetes Investigation</i> , 2012, 3, 498-502.	2.4	18
59	Glucagon-like peptide-1 secretion by direct stimulation of L cells with luminal sugar vs non-nutritive sweetener. <i>Journal of Diabetes Investigation</i> , 2012, 3, 156-163.	2.4	18
60	Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged $\geq 60$ years (START trial). <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1188-1192.	2.4	18
61	Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1211-1218.	2.4	18
62	Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity. <i>Journal of Diabetes Investigation</i> , 2019, 10, 902-905.	2.4	18
63	Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes. <i>BMJ Open</i> , 2021, 11, e045844.	1.9	18
64	The Role of Family Nutritional Support in Japanese Patients with Type 2 Diabetes Mellitus. <i>Internal Medicine</i> , 2010, 49, 983-989.	0.7	17
65	Smoking and adipose tissue inflammation suppress leptin expression in Japanese obese males: Potential mechanism of resistance to weight loss among Japanese obese smokers. <i>Tobacco Induced Diseases</i> , 2012, 10, 3.	0.6	17
66	Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes: Association of remaining $\beta$ -cell function and achievement of HbA1c target one year after initiation. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1203-1210.	2.3	17
67	Circadian rhythms and diabetes. <i>Journal of Diabetes Investigation</i> , 2011, 2, 176-177.	2.4	16
68	Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2011, 4, CMED.S5976.	1.9	16
69	Insulin Secretory Defect and Insulin Resistance in Isolated Impaired Fasting Glucose and Isolated Impaired Glucose Tolerance. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-8.	2.3	15
70	Endogenous GIP ameliorates impairment of insulin secretion in proglucagon-deficient mice under moderate beta cell damage induced by streptozotocin. <i>Diabetologia</i> , 2016, 59, 1533-1541.	6.3	15
71	Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse $\beta$ -cell function in the GetGoal-M and GetGoal-S trials. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1385-1392.	2.3	15
72	Bullous pemphigoid with dipeptidyl peptidase-4 inhibitors: Clinical features and pathophysiology. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1168-1170.	2.4	15

#	ARTICLE	IF	CITATIONS
73	Single-Cell Transcriptome Analysis Dissects the Replicating Process of Pancreatic Beta Cells in Partial Pancreatectomy Model. <i>IScience</i> , 2020, 23, 101774.	4.1	15
74	Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 659-670.	2.4	14
75	Relationship between deterioration of glycated hemoglobin lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2018, 9, 1153-1158.	2.4	14
76	Improvement of Fasting Plasma Glucose Level After Ingesting Moderate Amount of Dietary Fiber in Japanese Men With Mild Hyperglycemia and Visceral Fat Obesity. <i>Journal of Dietary Supplements</i> , 2013, 10, 129-141.	2.6	13
77	Circulating TNF receptor 2 is associated with the development of chronic kidney disease in non-obese Japanese patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2013, 99, 145-150.	2.8	13
78	Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1304-1309.	2.3	13
79	Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points. <i>Current Medical Research and Opinion</i> , 2015, 31, 1267-1270.	1.9	13
80	A Review of Recent Findings on Meal Sequence: An Attractive Dietary Approach to Prevention and Management of Type 2 Diabetes. <i>Nutrients</i> , 2020, 12, 2502.	4.1	13
81	A case of hypoglycemia due to illegitimate sexual enhancement medication. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, e8-e10.	2.8	12
82	Efficacy and Safety of Lixisenatide in Japanese Patients with Type 2 Diabetes Insufficiently Controlled with Basal Insulin±Sulfonylurea: A Subanalysis of the GetGoal-L-Asia Study. <i>Hormone and Metabolic Research</i> , 2015, 47, 895-900.	1.5	12
83	Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial. <i>Diabetology International</i> , 2021, 12, 87-100.	1.4	12
84	Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study. <i>Journal of Diabetes Investigation</i> , 2021, 12, 2162-2171.	2.4	12
85	Alogliptin benzoate for the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 851-863.	1.8	11
86	Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of <i>Journal of Diabetes Investigation</i> , 2015, 6, 201-209.	2.4	11
87	Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors. <i>Cancer Research</i> , 2020, 80, 3620-3630.	0.9	11
88	First Japanese Family With <i>PDX1</i> -MODY (MODY4): A Novel <i>PDX1</i> Frameshift Mutation, Clinical Characteristics, and Implications. <i>Journal of the Endocrine Society</i> , 2022, 6, bvab159.	0.2	11
89	Smoking, white blood cell counts, and TNF system activity in Japanese male subjects with normal glucose tolerance. <i>Tobacco Induced Diseases</i> , 2011, 9, 12.	0.6	10
90	Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in Japanese. <i>Journal of Diabetes Investigation</i> , 2012, 3, 377-383.	2.4	10

#	ARTICLE	IF	CITATIONS
91	Insulinoma with a History of Epilepsy: Still a Possible Misleading Factor in the Early Diagnosis of Insulinoma. <i>Internal Medicine</i> , 2017, 56, 3199-3204.	0.7	10
92	Hypoglycemia Unawareness in Insulinoma Revealed with Flash Glucose Monitoring Systems. <i>Internal Medicine</i> , 2018, 57, 3407-3412.	0.7	10
93	Generation and Characterization of a Novel Mouse Model That Allows Spatiotemporal Quantification of Pancreatic $\beta$ -Cell Proliferation. <i>Diabetes</i> , 2020, 69, 2340-2351.	0.6	10
94	Utility of microcatheter in adrenal venous sampling for primary aldosteronism. <i>British Journal of Radiology</i> , 2020, 93, 20190636.	2.2	10
95	Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials. <i>Journal of Diabetes Investigation</i> , 2022, 13, 975-985.	2.4	10
96	Enhanced glucagon-like peptide-1 secretion in a patient with glucagonoma: Implications for glucagon-like peptide-1 secretion from pancreatic $\beta$ cells in vivo. <i>Diabetes Research and Clinical Practice</i> , 2013, 102, e1-e4.	2.8	9
97	Circulating TNF Receptor 2 is Closely Associated with the Kidney Function in Non-Diabetic Japanese Subjects. <i>Journal of Atherosclerosis and Thrombosis</i> , 2014, 21, 730-738.	2.0	9
98	Mental distress and health-related quality of life among type 1 and type 2 diabetes patients using self-monitoring of blood glucose: A cross-sectional questionnaire study in Japan. <i>Journal of Diabetes Investigation</i> , 2018, 9, 1203-1211.	2.4	9
99	Dietary instructions focusing on meal-sequence and nutritional balance for prediabetes subjects: An exploratory, cluster-randomized, prospective, open-label, clinical trial. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107450.	2.3	9
100	Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1448-1456.	2.4	9
101	Dipeptidyl peptidase-4 inhibitors and prevention of bone fractures: Effects beyond glyemic control. <i>Journal of Diabetes Investigation</i> , 2012, 3, 347-348.	2.4	8
102	Cardiovascular safety trials of incretin-based drugs: What do they mean?. <i>Journal of Diabetes Investigation</i> , 2017, 8, 272-276.	2.4	7
103	Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (GlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 35-47.	4.4	7
104	Diabetes and COVID-19: IDF perspective in the Western Pacific region. <i>Diabetes Research and Clinical Practice</i> , 2020, 166, 108278.	2.8	7
105	Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index. <i>Journal of Diabetes Investigation</i> , 2022, , .	2.4	7
106	Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 249-264.	2.4	6
107	Low-carbohydrate diet by staple change attenuates postprandial GIP and CPR levels in type 2 diabetes patients. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107415.	2.3	6
108	Dietary recommendations for type 2 diabetes patients: Lessons from recent clinical and basic research in Asia. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1405-1407.	2.4	6



#	ARTICLE	IF	CITATIONS
109	Sphingosine kinase 1 interacting protein is a dual regulator of insulin and incretin secretion. <i>FASEB Journal</i> , 2019, 33, 6239-6253.	0.5	6
110	Real-world Observational Study on Patient Outcomes in Diabetes (RESPOND): study design and baseline characteristics of patients with type 2 diabetes newly initiating oral antidiabetic drug monotherapy in Japan. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001361.	2.8	6
111	The Role of Metagenomics in Precision Nutrition. <i>Nutrients</i> , 2020, 12, 1668.	4.1	6
112	Effects of ChREBP deficiency on adrenal lipogenesis and steroidogenesis. <i>Journal of Endocrinology</i> , 2021, 248, 317-324.	2.6	6
113	Healthcare resource utilization in patients treated with empagliflozin in East Asia. <i>Journal of Diabetes Investigation</i> , 2022, 13, 810-821.	2.4	6
114	A case of fulminant type 1 diabetes mellitus with exocrine pancreatic insufficiency and enhanced glucagon response to meal ingestion. <i>Diabetes Research and Clinical Practice</i> , 2008, 82, e1-e4.	2.8	5
115	A case of insulinoma with non-alcoholic fatty liver disease: Roles of hyperphagia and hyperinsulinemia in pathogenesis of the disease. <i>Endocrine Journal</i> , 2015, 62, 1025-1030.	1.6	5
116	Electrical properties of carbon-nanotube-network transistors in air after gamma irradiation. <i>Physica E: Low-Dimensional Systems and Nanostructures</i> , 2017, 86, 297-302.	2.7	5
117	The journey to understanding incretin systems: Theory, practice and more theory. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1171-1173.	2.4	5
118	Ceritinib associated hyperglycemia in the Japanese Adverse Drug Event Report Database. <i>Journal of Diabetes Investigation</i> , 2020, 11, 726-730.	2.4	5
119	Alcohol induced impaired insulin secretion in a Japanese population: 5 year follow up in the Cifu Diabetes Study. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1207-1214.	2.4	5
120	A novel RFX6 heterozygous mutation (p.R652X) in maturity onset diabetes mellitus: A case report. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1914-1918.	2.4	5
121	Low-dose Selective Arterial Calcium Stimulation Test for Localizing Insulinoma: A Single-center Experience of Five Consecutive Cases. <i>Internal Medicine</i> , 2020, 59, 2397-2403.	0.7	5
122	Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: A subgroup analysis of the PIONEER 9 and 10 Japanese trials. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 321-326.	4.4	5
123	High Protein Diet Feeding Aggravates Hyperaminoacidemia in Mice Deficient in Proglucagon-Derived Peptides. <i>Nutrients</i> , 2022, 14, 975.	4.1	5
124	Case 23-2018: A Man with Episodes of Confusion and Hypoglycemia. <i>New England Journal of Medicine</i> , 2018, 379, 1881-1882.	27.0	4
125	SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes. <i>Internal Medicine</i> , 2020, 59, 1535-1539.	0.7	4
126	The Smart Life Stay (SLS) program: effects of a lifestyle intervention program in combination with health tourism and health guidance for type 2 diabetes. <i>Nutrition and Diabetes</i> , 2020, 10, 33.	3.2	3



#	ARTICLE	IF	CITATIONS
127	Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA® Trial. <i>Diabetes Therapy</i> , 2020, 11, 1721-1734.	2.5	3
128	Tumor-like features of gene expression and metabolic profiles in enlarged pancreatic islets are associated with impaired incretin-induced insulin secretion in obese diabetes: A study of Zucker fatty diabetes mellitus rat. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1434-1447.	2.4	3
129	Carbonic anhydrase 8 (CAR8) negatively regulates GLP-1 secretion from enteroendocrine cells in response to long-chain fatty acids. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G617-G626.	3.4	3
130	Elevation of Fasting GLP-1 Levels in Child and Adolescent Obesity: Friend or Foe?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3778-e3780.	3.6	3
131	Voxel-based specific regional analysis system for Alzheimer's disease utility as a screening tool for unrecognized cognitive dysfunction of elderly patients in diabetes outpatient clinics: Multicenter retrospective exploratory study. <i>Journal of Diabetes Investigation</i> , 2021, , .	2.4	3
132	Semaglutide is effective in type 2 diabetes and obesity with schizophrenia. <i>Diabetology International</i> , 2022, 13, 693-697.	1.4	3
133	Relationship and factors responsible for regulating fasting and post-challenge plasma glucose levels in the early stage development of type 2 diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2014, 5, 663-670.	2.4	2
134	Reply to the comment of Wilbrink <i>et al</i> . on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining $\beta$ -cell function and the achievement of the HbA1c target 1 year after initiation. <i>Journal of Diabetes Investigation</i> , 2018, 9, 981-983.	2.4	2
135	A rare case of autoimmune polyglandular syndrome with Sjögren's syndrome and primary hypoparathyroidism. <i>BMJ Case Reports</i> , 2019, 12, e228634.	0.5	2
136	Factory-calibrated continuous glucose monitoring and capillary blood glucose monitoring in a case with insulinoma: usefulness and possible pitfall under chronic hyperinsulinemic hypoglycemia. <i>Endocrine Journal</i> , 2020, 67, 361-366.	1.6	2
137	Cardioprotective effects of GLP-1 (28-36a): A degraded metabolite or GLP-1's better half?. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1422-1425.	2.4	2
138	Diagnosis and treatment of primary central nervous system lymphoma with the primary lesion in the hypothalamus: a case report. <i>BMC Endocrine Disorders</i> , 2021, 21, 13.	2.2	2
139	iGlarLixi reduces residual hyperglycemia in Japanese patients with type 2 diabetes uncontrolled on basal insulin: A post-hoc analysis of the LixiLan JP trial. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1992-2001.	2.4	2
140	127-LB: Effectiveness and Safety of Empagliflozin in Routine Care in Europe and East Asia: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study. <i>Diabetes</i> , 2021, 70, 127-LB.	0.6	2
141	Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2795-2803.	4.4	2
142	Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 425-434.	2.4	2
143	Unmet needs in current clinical practice for insulinoma: Lessons from nationwide studies in Japan. <i>Journal of Diabetes Investigation</i> , 2022, 13, 429-431.	2.4	2
144	Alogliptin for the treatment of Type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 547-559.	2.4	1

#	ARTICLE	IF	CITATIONS
145	Total Ionizing Dose Effects in Carbon Nanotube Network Transistors. , 2015, , .		1
146	Use of the Japanese health insurance claims database to assess safety of SGLT2 inhibitors in the management of diabetes. Diabetes Research and Clinical Practice, 2016, 120, S52.	2.8	1
147	The Asian Association for the Study of Diabetes: The first 10Âyears and the next 10Âyears. Journal of Diabetes Investigation, 2020, 11, 1079-1084.	2.4	1
148	Effect of hypertriglyceridemia in dyslipidemiaâ€”induced impaired glucose tolerance and sex differences in dietary features associated with hypertriglyceridemia among the Japanese population: The Gifu Diabetes Study. Journal of Diabetes Investigation, 2021, 12, 771-780.	2.4	1
149	Hypoglycemic coma in an elderly adult switched from twice-daily vildagliptin to once-daily glimepiride to improve drug adherence. Diabetology International, 2022, 13, 295-299.	1.4	1
150	Effects of Dietary Instructions Including Meal-Sequence for Prediabetes Subjectsâ€”Comparison with Conventional Approach. Diabetes, 2018, 67, 53-LB.	0.6	1
151	1019-P: Glucagon-Like Peptide-1 Receptor Agonists Predominantly Reduce Body Fat Mass in Patients with Type 2 Diabetes. Diabetes, 2019, 68, 1019-P.	0.6	1
152	1660-P: Exome Sequencing in a Family with Multiple Cases of Early-Onset Diabetes Reveals a Candidate Causative Mutation in the PTF1A Gene. Diabetes, 2020, 69, 1660-P.	0.6	1
153	Glucokinase-maturity onset diabetes mellitus in the young suggested by factory-calibrated glucose monitoring data: a case report. Endocrine Journal, 2022, 69, 473-477.	1.6	1
154	PO046 COMPARISON OF FISH OR MEAT INTAKE BEFORE AND AFTER RICE ON POSTPRANDIAL GLUCOSE EXCURSIONS AND INCRETIN SECRETION IN TYPE 2 DIABETES: MEAL-SEQUENCE AS A NOVEL TARGET IN DIETARY THERAPY FOR DIABETES. Diabetes Research and Clinical Practice, 2014, 106, S68-S69.	2.8	0
155	Effects of SGLT2 inhibitor luseogliflozin under different dietary formula in type 2 diabetes: A randomized, controlled exploratory trial. Diabetes Research and Clinical Practice, 2016, 120, S52.	2.8	0
156	Comparison of short-and long-acting glucagon-like peptide 1 receptor agonists on postprandial glucose excursion, insulin and glucagon secretions and gastric emptying. Diabetes Research and Clinical Practice, 2016, 120, S124-S125.	2.8	0
157	Long-term glucose lowering effects of sitagliptin monotherapy and dietary contents in Japanese individuals with type 2 diabetes. Diabetes Research and Clinical Practice, 2016, 120, S128.	2.8	0
158	Efficacy and safety comparison of sitagliptin and glimepiride in elderly Japanese patients with type 2 diabetes: START-J. Diabetes Research and Clinical Practice, 2016, 120, S130-S131.	2.8	0
159	Clinical implication of diabetes education program declaring a goal in life for patients with diabetes mellitus. Diabetes Research and Clinical Practice, 2016, 120, S165.	2.8	0
160	Original diabetes education program including individual self-care plan â€œMy Goals Sheetâ€”ameliorates long-term glycemic control in patients with diabetes mellitus. Diabetes Research and Clinical Practice, 2016, 120, S177.	2.8	0
161	Cover Image, Volume 20, Issue 2. Diabetes, Obesity and Metabolism, 2018, 20, i-i.	4.4	0
162	A novel ultrasonography measurement of internal carotid artery stenosis: comparison with the North American Symptomatic Carotid Endarterectomy Trial angiographic method. Neurosonology, 2018, 31, 1-6.	0.0	0

#	ARTICLE	IF	CITATIONS
163	Response of a superconductor NbSe <sub>2</sub> flake to magnetic field detected with small tunnel junctions. <i>Journal of Physics: Conference Series</i> , 2019, 1293, 012016.	0.4	0
164	A case of MODY5-like manifestations without mutations or deletions in coding and minimal promoter regions of the <i>HNF1B</i> gene. <i>Endocrine Journal</i> , 2020, 67, 981-988.	1.6	0
165	Effects of physician's diabetes self-management education using Japan Association of Diabetes Education and Care Diabetes Education Card System Program and a self-monitoring of blood glucose readings analyzer in individuals with type 2 diabetes: An exploratory, open-labeled, prospective randomized clinical trial. <i>Journal of Diabetes Investigation</i> , 2021, . . .	2.4	0
166	Deterioration of HbA1c-Lowering Effects in Dipeptidyl-Peptidase Inhibitor and Dietary Habits in Japanese Type 2 Diabetes—Comparison with That of Metformin. <i>Diabetes</i> , 2018, 67, .	0.6	0
167	Safety and Tolerability of Empagliflozin in East Asian Patients with Type 2 Diabetes—Pooled Analysis of Phase I-III Clinical Trials. <i>Diabetes</i> , 2018, 67, 1150-P.	0.6	0
168	Factors Responsible for Progression of Microalbuminuria in Japanese Patients with Type 2 Diabetes-Retrospective Analysis. <i>Diabetes</i> , 2018, 67, 540-P.	0.6	0
169	2150-P: Single Cell RNA-Sequencing Dissects Proliferation of Pancreatic Beta Cells. <i>Diabetes</i> , 2019, 68, 2150-P.	0.6	0
170	41-OR: Store-Operated Ca <sup>2+</sup> Entry Activated by STIM1 Plays an Essential Role in GPR40-Mediated GII5 Potentiation. <i>Diabetes</i> , 2019, 68, 41-OR.	0.6	0
171	1018-P: Comparison of Short- and Long-Acting Glucagon-Like Peptide-1 Receptor Agonist Effects on Postprandial Glucose and Lipid Excursion via Gastric Emptying. <i>Diabetes</i> , 2019, 68, 1018-P.	0.6	0
172	110-OR: Generation of a Novel Mouse Model to Study $\beta$ -Cell Proliferation. <i>Diabetes</i> , 2019, 68, 110-OR.	0.6	0
173	786-P: Serum Dehydroepiandrosterone Sulfate Concentration and Animal Protein Intakes Are Important Factors for Skeletal Muscle Mass in Japanese Patients with Type 2 Diabetes. <i>Diabetes</i> , 2019, 68, 786-P.	0.6	0
174	771-P: Protein Intake at Breakfast Contributes to Maintenance of Skeletal Muscle Mass in Japanese Elderly Patients with Type 2 Diabetes. <i>Diabetes</i> , 2019, 68, .	0.6	0
175	1818-P: High-Sucrose Diet Causes Increased Hepatic Histone Acetylation Due to Increased Bacterial Acetate Production and Reduced Lipogenesis in ChREPB-Deficient Mice. <i>Diabetes</i> , 2020, 69, .	0.6	0
176	Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study. <i>Expert Opinion on Drug Safety</i> , 2022, . .	2.4	0